Firm Profile

Jason A. LeonardJason A. LeonardPartner, New York

Professional Experience

Jason Leonard has experience in all aspects of intellectual property law, with a focus on complex pharmaceutical patent litigation. Mr. Leonard has extensive experience litigating pharmaceutical patents in federal court, including appeals to the Court of Appeals for the Federal Circuit. Jason’s technical expertise includes new drug compounds, enantiomers, polymorphs, drug formulations, and methods of use.  He has litigated patents covering oncology drugs, antifungal agents, and oral contraceptives.  He has also advised clients regarding regulatory exclusivities at the U.S. Food and Drug administration, including patent term extensions, new chemical and product exclusivities, and GAIN.

Before practicing law, Mr. Leonard worked for six years as a solid-state and analytical chemist at Pfizer. His work included development of analytical methods for drug formulations and synthesis of novel polymorphs and salts of pharmaceutical compounds. He also specialized in conducting investigations of complex scientific problems encountered during drug development.  Mr. Leonard is a co-inventor on several solid-state pharmaceutical patents, including patents covering atorvastatin.

Awards and Recognition

Mr. Leonard is listed as a Rising Star in Intellectual Property Litigation in the 2015 issue of Super Lawyers: New York Metro Edition.

Education

J.D., cum laude, Franklin Pierce Law Center (now The University of New Hampshire), 2007
B.S., cum laude, Chemistry, The University of Connecticut, 1998 

Bar Admissions

U.S. Supreme Court, 2014; State of New York, 2008; State of New Jersey, 2007; U.S. District Court of New Jersey; U.S. District Courts for the Southern and Eastern Districts of New York

Professional Activities

New York Intellectual Property Law Association

Additional Publications

The Intellectual Property Review, “Chapter 33: United States” (Law Business Research Ltd., 4th ed. 2015)

The Intellectual Property Review, “Chapter 31: United States” (Law Business Research Ltd., 3rd ed. 2014)

The Intellectual Property Review, “Chapter 27: United States” (Law Business Research Ltd., 2d ed. 2013)

The Intellectual Property Review, “Chapter 24: United States” (Law Business Research Ltd. 2012)

“Solid-State Acid-Base Interactions in Complexes of Heterocyclic Bases and Dicarboxylic Acids: Crystallography, Hydrogen Bond Analysis and 15 N NMR Spectroscopy,” Journal of the American Chemical Society 2006.

Representative Matters

  • Merck in patent litigation involving its antifungal drug Cancidas® against Fresenius Kabi (2014-current)
  • Sanofi-Aventis in patent litigation involving its prostate cancer drug Jevtana® (2014-current)
  • Biotechnology Industry Organization (BIO) in petitioning as amicus curiae for a writ of certiorari in the U.S. Supreme Court in Baxter Int’l Inc. v. Fresenius USA, Inc. (2014)
  • Merck in patent litigation involving its antifungal drug Cancidas® against Xellia (2014-2015)
  • Warner Chilcott in patent litigation involving its oral contraceptive Loestrin24® (2012-2014)
  • Warner Chilcott in patent litigation involving its oral contraceptive LoLoestrin Fe® (2012-2014)
  • Merck in patent litigation involving its antifungal drug Cancidas® against Teva and Sandoz (2009-2012)
  • Sanofi-Aventis and Debiopharm in patent litigation involving its colorectal cancer drug Eloxatin® (2007-2010)

IN THE NEWS

Twenty-Two Fitzpatrick Partners Named As Top Intellectual Property Litigators
Super Lawyers: New York Metro Edition & Super Lawyers: Washington, D.C. Edition
September 2015

PRESS RELEASES

Fitzpatrick, Cella, Harper & Scinto LLP Names Three New Partners
January 8, 2016